Daiwa Securities Group Inc. Has $2.48 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Daiwa Securities Group Inc. cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,377 shares of the medical equipment provider’s stock after selling 4,028 shares during the period. Daiwa Securities Group Inc.’s holdings in Hologic were worth $2,478,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. General Partner Inc. bought a new stake in shares of Hologic in the 4th quarter valued at $26,000. Venturi Wealth Management LLC boosted its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the period. Finally, Smithfield Trust Co lifted its stake in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on HOLX. Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Citigroup reduced their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Evercore ISI lowered their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Shares of HOLX opened at $60.70 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market cap of $13.62 billion, a PE ratio of 19.15, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1 year low of $60.33 and a 1 year high of $84.67. The stock’s fifty day moving average price is $67.65 and its two-hundred day moving average price is $74.94.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.